DiaMedica Therapeutics Receives Health Canada Clearance to Launch Phase 2 Study of DM199 for Preeclampsia
DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia DiaMedica Therapeutics Inc. a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restriction and acute ischemic stroke (AIS), today announced that…
Silence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full-Year 2025 Financial Results
Silence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full Year 2025 Financial Results Silence Therapeutics plc, a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported financial results for the fourth quarter and full…
Affinia Therapeutics’ AFTX-201 Earns FDA Fast Track Designation for BAG3-Associated Dilated Cardiomyopathy
Affinia Therapeutics Granted FDA Fast Track Designation for AFTX-201 as a Treatment for People Living with BAG3-Associated Dilated Cardiomyopathy (DCM) Affinia Therapeutics an innovative gene therapy company with a pipeline of first-in-class and/or best-in-class adeno-associated virus (AAV) gene therapies initially…
HeartBeam Secures First Commercial Customer as ClearCardio Adopts 12-Lead ECG Technology
HeartBeam Announces First Commercial Customer as ClearCardio Brings Groundbreaking 12-Lead ECG Technology to High-Growth Preventive Cardiology Market HeartBeam, Inc. a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, announced a commercial partnership with ClearCardio™, a leading preventive…
Pulse Biosciences’ nPulse Vybrance System to Be Highlighted at North American Society for Interventional Thyroidology Meeting
Pulse Biosciences’ nPulse™ Vybrance™ System to be Featured in Multiple Presentations at the North American Society for Interventional Thyroidology Meeting Pulse Biosciences, Inc. developer of the novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™)…
Five Global Teams Receive $125 Million to Tackle Major Challenges in Cancer Science
Five Global Teams Awarded $125 Million to Take on the Toughest Challenges at the Frontiers of Cancer Science Cancer Grand Challenges, a global initiative co-founded by the National Cancer Institute in the US and Cancer Research UK, today announced a…
Stevanato Group Reports 7% Revenue Growth in FY2025 with Record High-Value Solutions Revenue
Stevanato Group Delivers 7% Revenue Growth (9% at Constant Currency) for Fiscal Year 2025, Including Record Revenue from High-Value Solutions and Expanded Margins Stevanato Group S.p.A. a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical,…
Verastem Oncology Reports 2025 Financial Results and Updates
Verastem Oncology Reports Strong Progress in 2025 with Drug Launch, Pipeline Advances, and Financial Updates Verastem Oncology reported its financial results for the fourth quarter and full year ending December 31, 2025, highlighting strong early revenue from its recently approved…
Seaport, Monash Awarded Up to $15M ARPA-H Grant for GlyphCele™
Seaport Therapeutics and Monash Institute of Pharmaceutical Sciences Awarded up to $15 Million from ARPA‑H to Advance Seaport’s GlyphCele™, the First Oral Therapeutic Designed to Restore Gut Lymphatic Function Seaport Therapeutics a clinical-stage therapeutics company advancing novel neuropsychiatric medicines with a…
Lucidis® Elevates Premium Cataract Surgery with Exceptional Full-Range Vision Performance
Lucidis® Sets High Standards in Premium Cataract Surgery with Full-Range Vision Performance Swiss Advanced Vision announces new clinical evidence confirming the exceptional performance of its Lucidis® intraocular lens (IOL), strengthening its position as a disruptive solution in premium cataract surgery.…
Syntis Bio Initiates Phase 1/1b Clinical Study of SYNT-101 in Obesity with First Patient Dosed
Syntis Bio Announces First Patient Dosed in Phase 1/1b Clinical Trial of SYNT-101 in Obesity and Key Leadership Additions Syntis Bio, Inc. a clinical-stage biopharmaceutical company advancing novel oral therapeutics that uniquely leverage the small intestine, today announced that the…
Polares Medical Boosts U.S. Expansion Plans with $50 Million Series C Following Encouraging Clinical Results
Polares Medical Raises $50 Million Series C to Advance U.S. Expansion of MRace Following Strong Clinical Results Polares Medical SA a clinical-stage structural heart company developing the MRace Posterior Leaflet Replacement (PLR) system for mitral regurgitation (MR), today announced the closing of…